

To: cupitt.larry@epa.gov <cupitt.larry@epa.gov>
From: Beatty, Patrick (PatrickBeatty) <PatrickBeatty@chevrontexaco.com>
Cc: Cagen, Stuart Z SCC-HSE <stuart.cagen@shell.com>
Bcc:
Received Date: 2004-05-12 23:49:48 GMT
Subject: RE: Benzene

Dr. Cupitt,

I don't mean to jump the gun so to speak, but in reading Stuart's e-mail I realized that he had not included my e-mail address or other contact information. The two EPA personnel that are most familiar with the benzene research project in Shanghai are Bob Sonawane and George Woodall. Bob as you may know is in NCEA in D.C. and George is in ORD in RTP. I would be happy to provide any details that I can.

Patrick Beatty, Ph.D., DABT
Staff Toxicologist
ChevronTexaco Energy Technology Company
(510) 242-7037
patrickbeatty@chevrontexaco.com

-----Original Message-----

From: Cagen, Stuart Z SCC-HSE [mailto:stuart.cagen@shell.com]
Sent: Wednesday, May 12, 2004 2:52 PM
To: cupitt.larry@epa.gov
Cc: Beatty, Patrick (PatrickBeatty)
Subject: Benzene

Larry:

You and I met recently as we are both members of the Steering Committee for the ILSI Biomonitoring Workshop.

Today's note pertains to recently initiated industry funded research program to better understand hazards and risks associated with benzene. The program has the cooperation and participation of a good portion of the medical community in Shanghai, China (including 26 hospitals) and includes the establishment of a new pathology laboratory in Shanghai. The study program includes consists of a disease progression study, a case control study, and a molecular epidemiology study. The molecular epidemiology study might be of special interest to you as it pertains to understanding biomarkers of benzene exposure.

My colleague Patrick Beatty of ChevronTexaco will soon be contacting Bob Sonawane, Bill Farland, and Peter Preuss of the EPA in order to set up a briefing meeting this summer (hopefully early - possibly the 3rd week in June). The meeting would be for purposes of informing the Agency of this program and to answer questions.

I am by no means an expert on who within the Agency would have an interest in this program outside of the names mentioned above, who I know would be interested from the perspective of benzene human health risk evaluation.

My request to you is to identify individuals - including yourself - who might also have an interest, particularly from the perspective of our molecular epidemiology study.

Please respond to myself, but also particularly to Patrick Beatty, so he can send a more functional note with respect to establishing a time, date and meeting location.

Thanks

Stuart

Stuart Cagen

Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 1407 Fax: +1 713 241 3325 Other Tel: +1 832 646 3987

Email: stuart.cagen@shell.com

Internet: <http://www.shell.com/chemicals>
